← Back to Screener
Aurinia Pharmaceuticals Inc (AUPH)
Price$15.96
Favorite Metrics
Price vs S&P 500 (26W)33.67%
Price vs S&P 500 (4W)4.99%
Market Capitalization$2.12B
P/E Ratio (Annual)7.38x
All Metrics
P/CF (Annual)15.63x
Book Value / Share (Quarterly)$4.39
P/TBV (Annual)3.64x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)28.31%
Cash Flow / Share (Quarterly)$1.02
Price vs S&P 500 (YTD)-3.51%
Gross Margin (TTM)88.46%
Net Profit Margin (TTM)101.47%
EPS (TTM)$2.08
10-Day Avg Trading Volume0.98M
EPS Excl Extra (TTM)$2.08
Revenue Growth (5Y)41.39%
EPS (Annual)$2.07
ROI (Annual)44.17%
Gross Margin (Annual)88.46%
Net Profit Margin (5Y Avg)-83.64%
Cash / Share (Quarterly)$3.01
P/E Basic Excl Extra (TTM)7.38x
Revenue Growth QoQ (YoY)28.81%
P/E Normalized (Annual)7.38x
ROA (Last FY)38.21%
Revenue Growth TTM (YoY)20.38%
EBITD / Share (TTM)$0.90
ROE (5Y Avg)-6.84%
Operating Margin (TTM)37.06%
Cash Flow / Share (Annual)$1.02
P/B Ratio3.65x
P/B Ratio (Quarterly)3.62x
Net Income / Employee (Annual)$1
EV / Revenue (TTM)7.45x
Net Interest Coverage (TTM)-7.31x
ROA (TTM)50.24%
EPS Growth QoQ (YoY)15987.37%
EV / EBITDA (TTM)16.96x
EPS Incl Extra (Annual)$2.07
Current Ratio (Annual)5.25x
Quick Ratio (Quarterly)4.70x
3-Month Avg Trading Volume1.06M
52-Week Price Return109.26%
EV / Free Cash Flow (Annual)15.57x
P/E Incl Extra (TTM)7.38x
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$4.36
P/S Ratio (Annual)7.49x
Asset Turnover (Annual)0.38x
52-Week High$16.54
Operating Margin (5Y Avg)-99.33%
EPS Excl Extra (Annual)$2.07
CapEx CAGR (5Y)-49.05%
Tangible BV CAGR (5Y)7.70%
26-Week Price Return42.41%
Quick Ratio (Annual)4.70x
13-Week Price Return5.38%
Total Debt / Equity (Annual)0.12x
Current Ratio (Quarterly)5.25x
Enterprise Value$2,108.907
Revenue / Share Growth (5Y)37.00%
Asset Turnover (TTM)0.50x
Book Value / Share Growth (5Y)6.42%
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)0.77x
Pretax Margin (Annual)40.33%
Cash / Share (Annual)$3.01
3-Month Return Std Dev33.88%
Gross Margin (5Y Avg)92.36%
Net Income / Employee (TTM)$1
ROE (Last FY)49.40%
Net Interest Coverage (Annual)-0.61x
EPS Basic Excl Extra (Annual)$2.07
P/FCF (TTM)15.66x
Receivables Turnover (TTM)7.26x
EV / Free Cash Flow (TTM)15.57x
Total Debt / Equity (Quarterly)0.12x
EPS Incl Extra (TTM)$2.08
Receivables Turnover (Annual)7.26x
ROI (TTM)59.83%
P/S Ratio (TTM)7.49x
Pretax Margin (5Y Avg)-95.04%
Revenue / Share (Annual)$2.04
Tangible BV / Share (Annual)$4.36
Forward P/E19.62x
Price vs S&P 500 (52W)74.16%
P/E Ratio (TTM)7.38x
EPS Growth TTM (YoY)5315.89%
Year-to-Date Return0.63%
5-Day Price Return-0.06%
EPS Normalized (Annual)$2.07
ROA (5Y Avg)-6.26%
Net Profit Margin (Annual)101.47%
Month-to-Date Return8.30%
Cash Flow / Share (TTM)$-0.49
EBITD / Share (Annual)$0.90
Operating Margin (Annual)37.06%
LT Debt / Equity (Annual)0.00x
P/CF (TTM)15.63x
ROI (5Y Avg)-7.14%
P/E Excl Extra (TTM)7.38x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$2.08
P/TBV (Quarterly)3.64x
P/B Ratio (Annual)3.62x
Inventory Turnover (TTM)0.77x
Pretax Margin (TTM)40.33%
Book Value / Share (Annual)$4.39
Price vs S&P 500 (13W)2.52%
Beta1.51x
P/FCF (Annual)15.66x
Revenue / Share (TTM)$2.05
ROE (TTM)70.37%
52-Week Low$7.29
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
3.92
3.92
3.92
3.92
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
AUPHAurinia Pharmaceuticals Inc | 7.49x | 20.38% | 88.46% | — | $15.96 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Aurinia Pharmaceuticals is a biopharmaceutical company specializing in autoimmune diseases with significant unmet medical needs. The company commercializes LUPKYNIS (voclosporin), the first and only FDA-approved oral therapy for active lupus nephritis in adult patients, and is developing aritinercept, a dual BAFF/APRIL inhibitor for additional autoimmune indications.